Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PSTV 
Plus Therapeutics Inc (PSTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: PSTV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.17
1 Year Target Price $9.17
| 1 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.98% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.21M USD | Price to earnings Ratio - | 1Y Target Price 9.17 |
Price to earnings Ratio - | 1Y Target Price 9.17 | ||
Volume (30-day avg) 4 | Beta 0.67 | 52 Weeks Range 0.16 - 2.31 | Updated Date 08/13/2025 |
52 Weeks Range 0.16 - 2.31 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -333.9% |
Management Effectiveness
Return on Assets (TTM) -105.59% | Return on Equity (TTM) -522.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34379165 | Price to Sales(TTM) 8.49 |
Enterprise Value 34379165 | Price to Sales(TTM) 8.49 | ||
Enterprise Value to Revenue 18.19 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 60490100 | Shares Floating 16972257 |
Shares Outstanding 60490100 | Shares Floating 16972257 | ||
Percent Insiders 1.7 | Percent Institutions 2.1 |
Upturn AI SWOT
Plus Therapeutics Inc
Company Overview
History and Background
Plus Therapeutics, Inc. (PSTV), formerly known as Cytori Therapeutics, was founded in 1996. It initially focused on regenerative medicine before shifting its focus to radiotherapeutics for cancer treatment. The company rebranded as Plus Therapeutics in 2018 to reflect its focus on targeted radiotherapeutics.
Core Business Areas
- Radiotherapeutics Development: Plus Therapeutics develops radiotherapeutics, drugs that deliver therapeutic doses of radiation directly to cancer cells.
- Rezalutu00ae: Rezalutu00ae is Plus Therapeutics' lead drug candidate, a radioisotope-filled liposome being developed to treat recurrent glioblastoma (rGBM) and leptomeningeal carcinomatosis (LMC).
- Drug Delivery Technology: The company utilizes its liposomal technology to deliver radioactive payloads, aiming to improve efficacy and reduce systemic toxicity.
Leadership and Structure
Marc Hedrick is the CEO of Plus Therapeutics. The company has a board of directors and a management team responsible for research and development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Rezalutu00ae: Rezalutu00ae (Rhenium-186 Nanoliposome) is Plus Therapeutics' lead product candidate for the treatment of recurrent glioblastoma (rGBM) and leptomeningeal carcinomatosis (LMC). Market share data is not applicable as the product is still in clinical development. Competitors developing therapies for rGBM and LMC include companies like Kazia Therapeutics (KZA.AX) and DNAtrix.
Market Dynamics
Industry Overview
The radiopharmaceutical industry is experiencing growth driven by advancements in targeted therapies and imaging techniques. Cancer treatment remains a significant area of unmet need, fostering innovation in radiotherapeutics.
Positioning
Plus Therapeutics is positioned as a developer of targeted radiotherapeutics, focusing on cancers with limited treatment options. Its liposomal delivery technology aims to improve drug delivery and reduce side effects.
Total Addressable Market (TAM)
The TAM for glioblastoma and leptomeningeal carcinomatosis is substantial, with potentially billions of dollars in revenue opportunity if effective treatments are developed. Plus Therapeutics' positioning within this TAM depends on the clinical success and eventual commercialization of Rezalutu00ae.
Upturn SWOT Analysis
Strengths
- Targeted radiotherapeutic approach
- Liposomal drug delivery technology
- Focus on unmet medical needs (rGBM and LMC)
Weaknesses
- Limited financial resources
- Reliance on single lead product candidate
- High clinical trial risk
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other cancer indications
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- KAZA.AX
- DNAtrix
Competitive Landscape
Plus Therapeutics competes with other companies developing therapies for rGBM and LMC, including those using different modalities (e.g., immunotherapy, gene therapy). Plus Therapeutics' advantage lies in its targeted radiotherapeutic approach.
Growth Trajectory and Initiatives
Historical Growth: Plus Therapeutics' historical growth is limited due to its pre-revenue status. Growth potential is tied to the clinical progress and eventual commercialization of Rezalutu00ae.
Future Projections: Future projections depend on clinical trial outcomes, regulatory approvals, and market adoption of Rezalutu00ae. Analyst estimates are highly speculative at this stage.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Rezalutu00ae in rGBM and LMC, and exploration of other potential applications of its radiotherapeutic platform.
Summary
Plus Therapeutics is a clinical-stage company developing targeted radiotherapeutics, primarily Rezalutu00ae, for difficult-to-treat cancers. Its success hinges on the positive results of its ongoing clinical trials. The company faces financial challenges and competition in the cancer therapy space, but its novel approach represents a potential strength. It requires funding for its trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Plus Therapeutics' SEC filings
- Company website
- Third-party financial data providers
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data and market share information are based on available public information and may be subject to change. Investing in pharmaceutical companies, especially clinical-stage companies, involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Plus Therapeutics Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2000-11-16 | President, CEO & Director Dr. Marc H. Hedrick M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://plustherapeutics.com |
Full time employees 21 | Website https://plustherapeutics.com | ||
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.